Pan‐Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma
The Journal of Gene Medicine · 2026-11 · 28 (11)
DOI: 10.1002/jgm.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 28.10.2026. Verfasst von Mi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Membrane Proteins, Biomarkers, Tumor, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Transmembrane protein 9 ( TMEM9 ) has been implicated in tumor progression, but its pan‐cancer diagnostic, prognostic, and immunological relevance remains incompletely characterized.
Methods
TMEM9 expression, diagnostic and prognostic value, genetic alterations, functional states, and immune associations were systematically evaluated using TCGA, GTEx, and complementary public cancer databases. Experimental validation was primarily performed in HNSC models using Western blotting, colony‐formation, wound‐healing, Transwell, and xenograft assays, with additional exploratory validation in RCC models.
Results
TMEM9 showed good‐to‐high diagnostic performance in 15 evaluable cancer cohorts, with particularly high AUCs in CHOL (1.000), KICH (0.970), LIHC (0.949), and THYM (0.925), whereas BRCA also showed strong discriminatory performance (AUC = 0.890). Higher TMEM9 expression was associated with unfavorable survival in several cancers, although its prognostic relevance varied by tumor type. TMEM9 expression was also associated with cancer‐related pathways, functional states, immune cell infiltration, and immunoregulatory gene expression in a context‐dependent manner. Experimentally, TMEM9 knockdown suppressed colony formation, wound closure, migration, and invasion in HNSC cells and inhibited FaDu xenograft growth. Similar inhibitory effects were additionally observed in exploratory RCC models.
Conclusion
TMEM9 exhibits cancer‐type–dependent diagnostic, prognostic, and immunological associations, whereas functional experiments support a tumor‐promoting role for TMEM9 in HNSC. Exploratory RCC experiments suggest that this effect may also occur in selected renal cancer cellular contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, Zhejiang, China.
- Internal Medicine of Traditional Chinese Medicine, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, Zhejiang, China.
- Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
- Department of Rehabilitation, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, Zhejiang, China.
ORCID-Profile: Youfeng Li
Zitieren
APA
Wang, M., Ying, S., Weng, C., & Li, Y. (2026). Pan‐Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma. The Journal of Gene Medicine, 28(11). https://doi.org/10.1002/jgm.70117
Vancouver
Wang M, Ying S, Weng C, Li Y. Pan‐Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma. The Journal of Gene Medicine. 2026;28(11). doi:10.1002/jgm.70117
BibTeX
@article{Wang2026,
author = {Wang, Mi and Ying, Shangyan and Weng, Chunyan and Li, Youfeng},
title = {Pan‐Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma},
journal = {The Journal of Gene Medicine},
year = {2026},
volume = {28},
number = {11},
doi = {10.1002/jgm.70117}
}
EUVIMED